EP
LXRX icon

Essential Partners’s Lexicon Pharmaceuticals LXRX Stock Holding History

Essential Partners’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-511
Closed -$690 – 2860
2025
Q3 		$690 Sell
511
-1,623
-76% -$1.84K ﹤0.01% 2128
2025
Q2 		$2.02K Buy
+2,134
New +$1.38K ﹤0.01% 1318

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Essential Partners's LXRX Position: Q4 2025 in Review

Essential Partners sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2025, closing a stake of 511 shares — an estimated $690 sold.

Essential Partners first reported a position in LXRX in Q2 2025 and held it in 2 quarters. The position peaked at $2.02K in Q2 2025. 125 funds tracked by Wall St. Rank hold LXRX as of Q4 2025.

  • Essential Partners reported no remaining Lexicon Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Essential Partners sold 511 Lexicon Pharmaceuticals shares in Q4 2025, an estimated $690.
  • Essential Partners first reported a position in Lexicon Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Essential Partners's Lexicon Pharmaceuticals position peaked at $2.02K in Q2 2025.
  • 125 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2025.

Based on Essential Partners's 13F filing for Q4 2025, filed 21 May 2026.